Guerbet Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Guerbet's estimated annual revenue is currently $575.7M per year.(i)
  • Guerbet's estimated revenue per employee is $201,000

Employee Data

  • Guerbet has 2864 Employees.(i)
  • Guerbet grew their employee count by 2% last year.

Guerbet's People

NameTitleEmail/Phone
1
Group CEOReveal Email/Phone
2
CFO Brazil (Jun 17- Feb 20) / CFO LatAm (Feb 20 - May 21) / North America Finance Director - CurrentReveal Email/Phone
3
CFO Brazil (Jun 17- Feb 20) / CFO LatAm (Feb 20 - May 21) / North America Finance Director - CurrentReveal Email/Phone
4
Executive Assistant to VP - North AmericaReveal Email/Phone
5
Global Chief Commercial OfficerReveal Email/Phone
6
Commercial VP, North AmericaReveal Email/Phone
7
North America Area VPReveal Email/Phone
8
Pharmacien AQ CMOReveal Email/Phone
9
SVP - Human Resources / CSRReveal Email/Phone
10
Head Global ServiceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31800M1095784%$367M$146B
Add Company

What Is Guerbet?

Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. \n\nA pioneer since more than 90 years in the field of contrast media, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019. \n\nIts total workforce is of over 2,800 employees. Achieve, Cooperate, Care and Innovate are the values that Guerbet's employees share and practice every day. Working at Guerbet means playing a unique part in the future of medical imaging. Passionate about its business, the company strive day in, day out to combine performance, quality and sustainable development. \n\nFor more information about Guerbet, please go to www.guerbet.com and follow Guerbet on Twitter @GuerbetGroup

keywords:N/A

N/A

Total Funding

2864

Number of Employees

$575.7M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Guerbet News

2022-04-17 - Guerbet: Q1 2022 revenue

Villepinte, Thursday, April 21, 2022 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging,...

2022-03-30 - Guerbet strengthens its Executive Committee with the ...

Villepinte, April 6, 2022 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and medical imaging solutions, has announced...

2022-03-22 - Guerbet - Gadopiclenol Marketing Authorization dossier ...

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical...

2021-10-28 - David Hale appointed CEO of Guerbet as from January 1, 2020 to accelerate deployment of the Group's strategy

Villepinte (France), December 18th, 2019 (6 :00 pm CEST) - Guerbet's Board of Directors announces the appointment of David Hale as Chief Executive Officer as from January 1, 2020. Chief Commercial Officer and Group Executive Committee member since February 2018, David Hale takes over the positi ...

2021-10-28 - Vectorio® Registration in India, An Innovative Medical Device for cTACE Procedures

Villepinte (France) - December 3, 2019 - 06:00pm - Guerbet (GBT) announces that the Ministry of Health & Family Welfare delivered registration for its innovative conventional Trans-Arterial Chemo-Embolization (cTACE) mixing and injection system, Vectorio®, in India. Vectorio® is a set of Lipiod ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A3058N/AN/A
#2
$1389.5M36768%N/A
#3
$3960M45073%N/A
#4
$750M4916N/AN/A
#5
$1494.2M620525%N/A